CureVac AG, which is developing vaccines based on messenger RNA technology, has raised $29.5 million from two new German investors to advance its portfolio. This follows a private share placement in 2015 that raised $110 million.
Evotec AG reported a 37% increase in revenue to €120.6 million for the first nine months as its drug discovery business on behalf of Sanofi SA moved into high gear and revenue from other long-term partners increased.
France-based Nicox SA said it anticipates a regulatory review of its glaucoma drug latanoprostene bunod to take place soon, and if the result is positive, the treatment could be on the US market by mid-2017.
AstraZeneca Plc is accelerating development of its oncology portfolio and tightening its therapeutic focus with an eye to returning to growth by 2018, or possibly earlier. The company’s third quarter results, released on 10 November, showed group revenue down by 4% to $5.7 billion, but new therapies in oncology and diabetes posted stronger sales.
Syncona LLP, the evergreen investment fund of the Wellcome Trust, is poised to increase its investment in UK life science through a merger with the Guernsey-based investment fund BACIT Ltd. The new group will keep the Syncona name and be listed on the London Stock Exchange.
MorphoSys AG has confirmed that its revenue this year is expected to be in a range of €47 million to €52 million and that its operating loss will amount to between €58 million and €68 million. The forecast was issued with the publication of the company’s third and nine-month results.
If the cell therapy industry were a housing project, then arguably it would be at the construction stage – deciding what materials are needed to make a safe and durable product. Manufacture is a key issue for the industry, but one that is just now being confronted, according to participants at a meeting of the Alliance for Regenerative Medicine that took place in London on 3 November.
Genmab A/S has raised its guidance for 2016 while announcing strong nine-month revenue, raising expectations that its partnered anticancer drug, Darzalex (daratumumab), will generate serious income in the future. The drug has received two breakthrough designations from the FDA..
The Food and Drug Administration has approved a new device for closing small holes in the heart called patent foramen ovales (PFO), which in some patients can be a cause of recurrent strokes. The non-surgical device can be inserted through a catheter in a vein in the leg.
H. Lundbeck A/S, the Danish pharmaceutical company specialising in psychiatric and neurological disorders, has raised its guidance for 2016 following a larger-than-expected increases in sales and earnings so far this year.